Robert Mayer ROBERT MAYER, Dana-Farber Cancer Institute, Boston One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some
Robert Mayer
ROBERT MAYER, Dana-Farber Cancer Institute, BostonOne of the leading participants at the 2008 Gastrointestinal Cancers Symposium,Robert Mayer, gave Peter Goodwin his assessment of some of the emerging new therapies being announced, for colorectal, liver and pancreas cancers.
Tags
Related Episodes
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer
Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study
Standing ovation at ASCO for RASolute 302 Study
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer